CARDINAL HEALTH INC

Cardinal Health's capital structure is highly leveraged, with a negative total equity of -$2.88 billion and long-term debt of $8.35 billion, resulting in a debt-to-equity ratio of -2.89. Despite this, the company maintains a market cap of $46.47 billion and a price-to-earnings ratio of 50.67, indicating a premium valuation relative to earnings. The company's liquidity position is mixed, with $2.78 billion in cash and equivalents but a current ratio of 0.91, suggesting current liabilities exceed current assets. Profitability metrics show a mixed picture. The company reported a net income of $917 million for the quarter, but its return on equity is negative at -31.8%, reflecting the negative equity position. Return on assets is low at 1.58%, below the industry median for pharmaceuticals. Operating income of $1.38 billion is also below the industry median, indicating underperformance in core operations. Geographically, Cardinal Health's revenue is concentrated in the United States, with limited exposure to international markets. The company's revenue concentration in the U.S. is a key risk factor, as it exposes the business to domestic regulatory and economic shifts. The company's segments include Branded Pharmaceuticals, which saw increased demand for GLP-1 pharmaceuticals in the prior period. Growth trajectory is mixed. The company's revenue for the quarter was $12.96 billion, but GAAP operating earnings for the three months ended March 31, 2026, were $509 million, a 30% decline from the prior year. Non-GAAP operating earnings, however, increased by 18% to $956 million, driven by cost management and restructuring efforts. The company's capital expenditure of $239 million reflects ongoing investment in infrastructure. Risk factors include high liquidity risk due to the current ratio below 1 and negative net cash after subtracting total debt. The company also faces potential dilution risk, though it could not be assessed due to missing basic and diluted share counts. The risk assessment flags current liabilities exceeding current assets as a key concern. Recent events include a $184 million pre-tax non-cash goodwill impairment charge related to the Navista & ION reporting unit within the Pharma segment. The company also reported net recoveries in class action antitrust litigation in prior periods, which positively impacted GAAP operating earnings. Management's forward-looking statements in the 10-Q highlight ongoing challenges and opportunities, including increased demand for GLP-1 pharmaceuticals.